Navigation Links
Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose

Data Presented as Poster Presentation at the Associated Professional Sleep

Societies 2008 Annual Meeting

BALTIMORE, June 11 /PRNewswire/ -- Data was presented today at the 22nd Annual Meeting of the Associated Professional Sleep Societies (APSS) demonstrating that within 20 minutes of administration, Intermezzo(R), an investigational low-dose, sublingual formulation of zolpidem, delivered overall bioavailability that was significantly greater than that produced by a swallowed Ambien(R) tablet containing a zolpidem dose that was nearly 3 times higher. Despite this higher initial bioavailability, zolpidem blood levels from sublingual 3.5 mg Intermezzo(R) were significantly lower four hours after administration than the levels produced by the 10 mg Ambien(R) dose. Transcept Pharmaceuticals is developing Intermezzo(R) for the treatment of insomnia characterized by middle-of-the-night (MOTN) awakenings with difficulty returning to sleep.

"One significant challenge in trying to help insomnia patients return to sleep after a middle-of-the-night awakening is that the most commonly prescribed bedtime medications are not designed to be taken as needed in the middle of the night without risking significant drowsiness the following day," said Thomas Roth, Ph.D., Chief of Sleep Medicine, Henry Ford Hospital Sleep Disorders and Research Center in Detroit and principal investigator in this study. "The only recourse to date for patients has been either to try to predict what nights they will awaken, or to take sleep medication every night at bedtime. Studies of Intermezzo(R) show promise in offering the first viable, 'use only when needed' option for treating awakenings in the middle of the night when they occur."

Intermezzo(R): Rapid bioavailability despite a lower dose

In the pharmacokinetic comparison study presented at APSS, 36 healthy subjects between the ages of 19 and 64 were randomized to receive either a 3.5 mg. Intermezzo(R) sublingual lozenge or a 10 mg. Ambien(R) tablet following an overnight fast. Bioavailability assessments began prior to dosing and continued for eight hours. Although Ambien(R) doses were approximately three times higher than those of Intermezzo(R), overall bioavailability at 5 minutes, 10 minutes and 20-minutes was significantly higher for Intermezzo 3.5 mg compared to Ambien(R) 10 mg. In a previous clinical sleep laboratory study, Intermezzo(R) 1.75 mg and 3.5 mg demonstrated a statistically significant improvement in latency to sleep onset vs. placebo; these are the lowest doses of zolpidem ever shown to be statistically effective vs. placebo in inducing sleep.

Another of the study's authors, Andrew Krystal, M.D., Associate Professor and Director of the Duke Clinic Sleep Laboratory, commented, "The Intermezzo(R) sublingual delivery system appears to markedly increase the early uptake of zolpidem. Combining early bioavailability with a low dose may offer patients who wake up in the middle of the night help in returning to sleep while potentially avoiding next day residual effects."

MOTN Awakenings: Redefining Insomnia

Middle-of-the-night (MOTN) or nocturnal awakenings have been reported to be one of the most common sleep problems, affecting approximately one-third of the adult population. According to a recent epidemiological study ("Nocturnal awakenings and comorbid disorders in the American general population" -- Journal of Psychiatric Research [in press], Maurice M. Ohayon, MD, DSc, PhD.), nocturnal awakenings are the most frequently reported insomnia symptom in the general population, with 35 percent of Americans experiencing awakenings at least three times per week and 23 percent waking up at least once every night. Ninety percent of the MOTN insomnia population report that their pattern of awakenings persists for at least six months and 50 percent report such insomnia problems lasting more than 5 years. Currently, there is no approved PRN ("use only when needed") treatment for MOTN insomnia.

"The prevalence and impact of nocturnal awakenings may require significant adjustments in how we define, diagnose and treat insomnia, which is currently approached in a one-size-fits-all fashion due to the limitations of available therapies," said Dr. Roth, who participated in a June 2008 APSS symposium convened to discuss the prevalence and consequences of nocturnal awakenings.

A Potential New Approach for Patients with Middle of the Night Awakenings

In a related APSS poster presentation, investigators described a study in which they sought to quantify the proportion of MOTN insomnia patients who would be suitable candidates for treatment with a rapidly effective and short-acting agent. Investigators monitored 654 patients participating in an insomnia clinical trial using an Interactive Voice Response System (IVRS) that patients called each night after a middle of the night awakening. This system tracked the time of awakenings and amount of bedtime remaining.

Of the original group, 300 met the study criteria and were verified to suffer from MOTN awakenings with difficulty returning to sleep. These patients experienced a weekly average of 5.2 such awakenings and more than 90 percent of these awakenings occurred with at least four hours of bedtime remaining.

"Nearly all patients in this study experienced frequent awakenings at a time of night when they had at least four hours of sleep remaining. Thus, they would be appropriate candidates for treatment with a rapid-acting, low-dose medication," said Russell Rosenberg, Ph.D., principal study author and Director, NeuroTrials Research and the Atlanta School of Sleep Medicine. "The study underscored the potential for Intermezzo(R) to be useful in a patient population such as this."

About Zolpidem

To date, zolpidem has been available in the United States as the active agent in Ambien(R) and Ambien CRTM, prescribed for adults at 10 mg and 12.5 mg doses respectively. These amounts are between three and four times the highest Intermezzo(R) dose available.

It is estimated that over 15 billion doses of zolpidem have been prescribed since its original approval by the FDA. Zolpidem has been shown to be safe and effective for the treatment of insomnia, but the high dose products available in the U.S. and elsewhere have been designed to produce 6 to 8 hours of sleep, and are thus unsuitable for "as needed" treatment of patients who awaken in the middle of the night and have fewer hours remaining before waking up in the morning.

About Intermezzo(R)

Intermezzo(R) (zolpidem tartrate sublingual lozenge) employs Transcept Pharmaceuticals' proprietary Bimucoral(R) technology in a mint-flavored, sublingual lozenge formulated to dissolve under the tongue in approximately two minutes. This novel approach has been shown to accelerate the bioavailability of zolpidem, despite the substantially lower Intermezzo(R) dose vs. the doses employed with previously available forms of the drug.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product candidate, Intermezzo(R) (zolpidem tartrate sublingual lozenge), is a low dose formulation of zolpidem for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and Transcept plans to submit an NDA in the third quarter of 2008. Transcept is also developing TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. For further information, please visit the company's website at:


The Ruth Group

Transcept Pharmaceuticals, Inc. Investors / Media

Michael Gill Stephanie Carrington / Jason Rando

Director of Communications (646) 536-7017 / 7025

(510) 215-3575

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
2. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
3. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
4. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
5. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
6. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
7. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
8. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
9. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
10. Bionomics Achieves US$1 Million Milestone Payment from Genmab
11. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
Post Your Comments:
(Date:10/13/2015)... 13, 2015  Human Longevity, Inc. (HLI), the genomics-based, ... announced today the launch of the company,s first Health ... the potential to transform healthcare. The inaugural Health Nucleus ... , at HLI,s headquarters facility. More Health Nucleus facilities ... and International cities. --> ...
(Date:10/13/2015)... -- Synapse Biomedical Inc. ( ) reported today that ... use of the NeuRx ® Diaphragm Pacing System ... the United States and patient ... PAS study group met their initial enrollment goal ahead ... expanded the enrollment target to 150 participants.   ...
(Date:10/13/2015)... , Oct. 13 2015 ... addition of the "US & European ... Countries (2010-2021)" report to their offering. ... the addition of the "US & ... 16 Countries (2010-2021)" report to their ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... “Women have 2 questions when they ... to live?’ The second is, “Will I lose my hair?’” , Carly Klein is ... women with licensed medical professionals to develop personalized hair loss treatment plans. With 10 ...
(Date:10/13/2015)... — , ... ... Association of America (MOAA) will hold its 2015 annual meeting ... a free military career fair; informational seminars; a luncheon featuring ... the Joint Chiefs of Staff; and the Community Heroes Award ...
(Date:10/13/2015)... ... ... The American Institutes for Research ( AIR ) developed a collection of guides ... sexual assault and other trauma. The toolkit, funded by the U.S. Department of Education, ... 21st anniversary. , AIR developed the Safe Place toolkit in ...
(Date:10/13/2015)... ... 13, 2015 , ... "My friend's son suffers from eczema, and he had ... an inventor from Platteville, Colo. "I came up with this kit as a way ... to prevent a child from rubbing or scratching his or her face. This protects ...
(Date:10/13/2015)... , ... October 13, 2015 , ... According to an ... recent study has shown that women who successfully lose weight with a bariatric procedure ... United States each year. The article notes that anywhere from 40 to 50 percent ...
Breaking Medicine News(10 mins):